ZURA (Zura Bio) Forward Dividend Yield % : 0.00% (As of May. 06, 2025)

View and export this data going back to 2023. Start your Free Trial

What is Zura Bio Forward Dividend Yield %?

As of today (2025-05-06), the Forward Annual Dividend Yield of Zura Bio is 0.00%.

As of today (2025-05-06), the Trailing Annual Dividend Yield of Zura Bio is 0.00%.

ZURA's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.53
* Ranked among companies with meaningful Forward Dividend Yield % only.

Zura Bio's Dividends per Share for the three months ended in Dec. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Zura Bio's Forward Dividend Yield %

For the Biotechnology subindustry, Zura Bio's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zura Bio's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zura Bio's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Zura Bio's Forward Dividend Yield % falls into.

Save Embed

;

Save Embed

;

Zura Bio Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Zura Bio (NAS:ZURA) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Zura Bio Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Zura Bio's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Zura Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zura Bio Ltd (NAS:ZURA) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1489 W. Warm Springs Road, Suite 110, Henderson, NV, USA, 89014

Website

https://www.zurabio.com

Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

Executives

Parvinder Thiara	director, 10 percent owner	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Someit Sidhu	director	C/O MAPLES CORPORATE SERVICES LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-11
Ploos Van Amstel Arnout	director	C/O MAPLES CORPORATE SERVICES LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-11
Amit Munshi	director	C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116
Michael Howell	officer: SVP, Translational Medicine	4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA CA 92037
Garry Arthur Neil	director	555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Ewon Comfortech Co., Ltd.	10 percent owner	8, CHEOMDAN 1-RO, JEONGUP-SI, JEONLABUK-DO M5 320836
Chris Kim	10 percent owner	6 CENTERPOINTE DR., #625, LA PALMA CA 90623
Hana Immunotherapeutics Llc	10 percent owner	6 CENTERPOINTE DR., #625, LA PALMA CA 90623
Theresa Lowry	officer: EVP and CHRO	3629 VILLA TERRACE, SAN DIEGO CA 92104
Gary Whale	officer: EVP and CTO	2 THE BEACHES, SHIPLAKE, HENLEY-ON-THAMES, OXFORDSHIRE X0 RG9 3BT
Kimberly Ann Davis	officer: Secretary and General Counsel	C/O ZURA BIO INC., 4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA CA 92037
Graham Neil Murray Hamilton	director	33 MT. GREEN RD, CROTON ON HUDSON, NEW YORK NY 10520
Sandeep Chidambar Kulkarni	director	92 MORNINGSIDE AVE., APT 7E, NEW YORK NM 10027
Pfizer Inc	10 percent owner	66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192